Two Drugs for Advanced Lung Cancer With KRAS Mutation
Part of Cancer clinical trials.
This trial tests two drugs (luvometinib and anlotinib) together to treat advanced lung cancer that has a KRAS mutation and has grown despite previous treatment. The goal is to see if this combination helps patients live longer and slows cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Advanced (stage IV) non-small cell lung cancer confirmed by biopsy or tissue sample
- Cancer has a KRAS mutation (a specific genetic change)
- You've already received at least one prior treatment (like chemotherapy or immunotherapy) and your cancer got worse
- Good overall health (able to perform daily activities with little or no assistance)
- Expected to live at least 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (trametinib, anlotinib, and tislelizumab) for people with KRAS-mutant non-small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This study tests a new combination of two targeted drugs (andamertinib and anlotinib) for lung cancer that has EGFR mutations and has progressed after a prior EGFR TKI. It aims to see if the combination can shrink tumors and help control the cancer.
This study tests whether taking dacomitinib plus anlotinib as a first treatment can shrink or control advanced lung cancer that has the EGFR L858R mutation. It may help people who have not had any standard drug treatment yet, especially if their brain metastases are stable.
This trial tests a combination of radiation therapy and a targeted drug (Anlotinib) for people with a type of advanced lung cancer that cannot be treated with standard chemoradiation. It may help if your cancer has not spread to other parts of the body and you have not had certain prior treatments.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Hear when a new Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.